目的 探討麝香通心滴丸聯(lián)合美托洛爾治療冠心病心絞痛的臨床療效和安全性。方法 選取2015年12月—2017年1月上海市浦東醫(yī)院收治的冠心病心絞痛患者90例，隨機(jī)分為對(duì)照組和治療組，每組各45例。對(duì)照組患者口服酒石酸美托洛爾緩釋片，5 mg/次，2次/d，依據(jù)患者耐受程度和病情逐漸加量到10～25 mg/次，2次/d。治療組在對(duì)照組的基礎(chǔ)上口服麝香通心滴丸，2丸/次，3次/d。兩組患者治療時(shí)間均為2個(gè)月。觀察兩組患者臨床療效，比較治療前后兩組患者心電圖療效、心絞痛持續(xù)時(shí)間和發(fā)作次數(shù)、ST段及不良反應(yīng)情況。結(jié)果 治療后，對(duì)照組臨床有效率和心電圖療效分別為77.7%和75.6%，均分別低于治療組的93.3%和95.6%。兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組患者心絞痛持續(xù)時(shí)間和發(fā)作次數(shù)及ST段均顯著降低，同組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組上述指標(biāo)改善后水平顯著低于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療中，治療組不良反應(yīng)發(fā)生率為4.4%，明顯低于對(duì)照組的13.3%，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 麝香通心滴丸聯(lián)合美托洛爾治療冠心病心絞痛臨床療效顯著，有助于減少心絞痛發(fā)作次數(shù)和持續(xù)時(shí)間，安全性高，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To investigate the clinical efficacy and safety of Shexiang Tongxin Dropping Pills combined with metoprolol in treatment of coronary heart disease with angina pectoris. Methods Patients (90 cases) with coronary heart disease and angina pectoris in Shanghai Pudong Hospital from December 2015 to January 2017 were randomly divided into control and treatment groups, and each group had 45 cases. Patients in the control group were po administered with Metoprolol Tartrate Sustained-release Tablets, 5 mg/time, twice daily, and the dosage was increased to 10-25 mg/time based on patient's tolerance and condition. Patients in the treatment group were po administered with Shexiang Tongxin Dropping Pills on the basis of the control group, 2 pills/time, three times daily. Patients in two groups were treated for 2 months. After treatment, the clinical efficacy was evaluated, and the electrocardiogram efficacy, the frequency and duration of angina pectoris, ST segment, adverse reactions in two groups before and after treatment were compared. Results After treatment, the clinical and electrocardiogram efficacy in the control group were 77.7% and 75.6%, which were significantly lower than 93.3% and 95.6% in the treatment group, respectively, and there were differences between two groups (P < 0.05). After treatment, the frequency and duration of angina pectoris, ST segment in two groups were significantly decreased, and there were differences in the same group (P < 0.05), and these indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P < 0.05). During the treatment, the incidence of adverse reactions in the treatment group was 4.4%, which was significantly lower than 13.3% in the control group, with significant difference between two groups (P < 0.05). Conclusion Shexiang Tongxin Dropping Pills combined with metoprolol has significant clinical effect in treatment of coronary heart disease with angina pectoris, which is conducive to reduce the frequency and duration of angina pectoris, with good safety, which has a certain clinical application value.

上海市浦東新區(qū)衛(wèi)生系統(tǒng)學(xué)科帶頭人培養(yǎng)計(jì)劃（PWRd2013-06）